Table 2.
The evolution of urgency in the course of the study.
| Variable | Baseline n (%) [B] |
Week 1 n (%) [W1] |
Week 6 n (%) [W6] |
Statistical analyses inside each group |
|---|---|---|---|---|
| Control group (n=110) [C] |
29 (26.4) | 66 (60.0) | 23 (20.9) | B vs. W1, p <0.001 B vs. W6, NS W1 vs. W6, p <0.001 |
|
| ||||
| Treatment group 1 (10 mg of solifenacin) (n=114) [S] |
35 (30.7) | 43 (37.7) | 11 (9.7) | B vs. W1, NS B vs. W6, p < 0.001 W1 vs. W6, p < 0.001 |
|
| ||||
| Treatment group 2 (50 mg of mirabegron) (n=104) [M] |
26 (25) | 43 (41.3) | 23 (22.1) | B vs. W1, p<0.05 B vs. W6, NS W1 vs. W6, p<0.005 |
Baseline: C vs. S (NS); C vs. M (NS); S vs. M (NS).
Week 1: C vs. S (p <0.001); C vs. M (p <0.001); S vs. M (NS).
Week 6: C vs. S (p<0.05); C vs. M (NS); S vs. M (p<0.05).